Lenvatinib-Pembrolizumab Combo Misses on Survival in Endometrial Cancer Trial

(MedPage Today) -- SAN DIEGO -- A combination of lenvatinib (Lenvima) and pembrolizumab (Keytruda) failed to meet survival endpoints compared with chemotherapy as first-line therapy for patients with advanced or recurrent endometrial cancer...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news